IPCA Laboratories Limited (IPCA) was incorporated on 19th October 1949 under the name of 'The Indian Pharmaceutical Combine Association Limited.' Ipca Laboratories is the largest pharmaceutical Company known for manufacturing and exporting over 350 formulations and 80 APIs globally since 1949. The company has emerged as a leading player in the pharmaceutical industry, transforming from a small enterprise into a major global pharmaceutical manufacturer over more than seven decades.
Ipca is a fully-integrated Indian pharmaceutical company manufacturing over 350 formulations and 80 APIs for various therapeutic segments. The company operates as a comprehensive pharmaceutical manufacturer, covering the entire spectrum from active pharmaceutical ingredients to finished formulations. For more than 60 years, Ipca has been a crucial healthcare partner in over 120 countries across the 6 continents.
As of the latest financial data, Ipca Laboratories Ltd has a market capitalisation of Rs 34,685 crore. The company has demonstrated strong financial performance in recent quarters. On a consolidated basis, Ipca Laboratories Ltd reported a profit of Rs 65.78 crore on a total income of Rs 2,272.51 crore for the quarter ended 2025. For the year ended 2024, Ipca Laboratories Ltd had posted a profit of Rs 529.21 crore on a total income of Rs 7,705.04 crore.
The company has shown impressive growth trajectory in recent periods. For the full year,net profit rose 34.77% to Rs 737.68 crore in the year ended March 2025 as against Rs 547.35 crore during the previous year ended March 2024. Sales rose 16.02% to Rs 8939.59 crore in the year ended March 2025 as against Rs 7705.04 crore during the previous year ended March 2024.
**Key Financial Highlights:**
- **Market Cap**: Rs 34,685 crore (as of latest data)
- **Revenue FY25**: Rs 8,939.59 crore (up 16.02% YoY)
- **Net Profit FY25**: Rs 737.68 crore (up 34.77% YoY)
- **Q3 FY25 Revenue**: Rs 1,662.68 crore (up 10.34% YoY)
- **Q3 FY25 Net Profit**: Rs 248.14 crore (up 37.95% YoY)
IPCA Laboratories operates through two primary business segments - formulations and active pharmaceutical ingredients (APIs). Ipca produces over 80 APIs, nearly 79% of the APIs and Intermediates business is from exports making them one of India's top exporters of APIs, serving over 100 countries around the globe. Today, we are one of the world's largest manufacturers and suppliers of over a dozen APIs.
The company has established a strong presence in various therapeutic segments. It offers APIs, such as Atenolol, Chloroquine Phosphate, Chlorthalidone, Furosemide, Hydroxychloroquine sulfate, Losartan, Metoprolol Succinate, Metoprolol Tartrate, Pyrantel Salts and Propranolol. The Company offers brands, such as Zerodol, Lariago, HCQS, Perinorm, Rapither AB, Tenoric, Lumerax, Etova, Fexova, Malirid, Allsuth, Alwiz, AZR 50mg, Bacilon, Cinkona, Clarbact, Glyree MV, Halotop, Luliz, Ozepam, Pacimol, Pari, Xtor-F, Zabpro, Zilast, Ramcor, Sove, Venpower and Folitrax.
Since 1949, Ipca's wide network of manufacturing units has expanded to 15 locations across the globe, including our API manufacturing facility in North Carolina, USA. The company has built a robust manufacturing infrastructure that enables it to serve global markets effectively. The Company has 18 manufacturing units in India manufacturing API's and formulations.
These are produced from scratch at fully-automated manufacturing facilities, approved by the world's most discerning drug regulatory authorities like UK-MHRA, EDQM-Europe, and WHO-Geneva, among others. The company has received various international certifications and approvals, establishing its credibility in global pharmaceutical markets.
The products of the Company are sold in over 100 countries across the globe. IPCA has established a significant international footprint, with exports forming a substantial portion of its revenue. With a reliable supply chain and cost competitiveness in the dynamic market, Ipca has emerged as one of India's top API exporters.
The company has a notable presence in key international markets. With more than 25 years of presence in Russia, Ipca Laboratories has grown as the top leader in manufacturing and exporting high-grade generic and branded drugs. With a presence in Russia for more than 25 years, Ipca has built a strong equity of its brands making us one of the leading companies from India in the market.
Promoter holding in Ipca Laboratories Ltd has gone down to 44.72 per cent as of Mar 2025 from 46.30 per cent as of Jun 2024. The company maintains a balanced shareholding structure with professional management under the leadership of experienced promoters.
The company has shown strong operational performance in recent quarters. Ipca Laboratories achieved 18% revenue growth in FY25, with EBITDA rising 29.8%. The company remains optimistic about future growth in chronic care and pain management segments. Ipca to market NovaLead's patented, repurposed drug Diulcus® for the treatment of Diabetic Foot Ulcer (DFU) The approval is based on Phase III study which established that NovaLead's patented drug branded as Diulcus®, which will be marketed in India by Ipca. Diulcus® promotes the complete closure of DFU significantly better than Standard of Care, which is the present treatment of choice.
IPCA Laboratories continues to maintain its position as a leading pharmaceutical company with a strong focus on research and development, manufacturing excellence, and global market expansion. The company's integrated business model, covering both APIs and formulations, positions it well to capitalize on the growing pharmaceutical market both domestically and internationally.
